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Background: According to the “autovaccination hy-
pothesis,” reexposure to human immunodeficiency vi-
rus (HIV) during treatment interruptions may stimu-
late the HIV-specific immune response and lead to low
viremia after withdrawal of highly active antiretroviral
treatment (HAART). Many patients who started HAART
earlier in their disease course than is currently recom-
mended would like to discontinue, but it is unknown
whether it is safe to do so.
Objectives: To determine whether repeated treatment
interruptions of HAART (1) stimulated the cytotoxic
HIV-specific immune response and whether such
stimulation correlated with low viremia off treatment,
and (2) were safe with respect to clinical complications,
development of viral resistance, and decline in CD4 cell
counts.
Design: Interventional study with before-after compari-
son.
Setting: Outpatient clinics of university hospitals in Swit-
zerland and Spain.
Patients: A total of 133 patients receiving HAART, with
a median CD4 cell count of 740/µL, and whose viral load
had been undetectable for a median of 21 months.
Interventions: HAART was interrupted for 2 weeks, re-
started, and continued for 8 weeks. After 4 such cycles,
treatment was indefinitely suspended 40 weeks after study
entry.
Main Outcome Measures: HIV-specific cytotoxic T-
cell responses were evaluated by interferon  enzyme-
linked immunospot analysis. The proportion of “respond-
ers” (viral load 5000 copies/mL) was measured at weeks
52 and 96. HIV-related diseases and CD4 cell counts were
recorded.
Results: Seventeen percent of patients (95% confi-
dence interval, 11%-25%) were responders at week 52,
and 8% at week 96. Low pre-HAART viral load and lack
of rebound during weeks 0 to 40 predicted response. HIV-
specific CD8+ T cells increased between week 0 (me-
dian, 343 spot-forming cells per million peripheral blood
lymphocytes [SFC/106 PBL]) and week 52 (median, 1930
SFC/106 PBL), but there was an inverse correlation be-
tween response and the number of spot-forming cells.
Eighty-five (64%) of 133 patients stopped therapy for at
least 12 weeks, and 55 (41%) for at least 56 weeks. The
median CD4 cell count decreased from 792/µL to 615/µL
during the first 12 weeks without treatment, but stabi-
lized thereafter. One patient (0.75%) developed drug re-
sistance necessitating salvage treatment. There were no
AIDS-related clinical complications.
Conclusions: Results of this study do not favor the au-
tovaccination hypothesis. Treatment interruptions did not
provoke clinical complications, and there was little drug
resistance. Comparative trials will have to show what ben-
efit, if any, is associated with intermittent, as opposed to
continuous treatment.
Arch Intern Med. 2003;163:1220-1226
A
FTER INTRODUCTION of
highly active antiretroviral
treatment (HAART), mor-
bidity and mortality of hu-
man immunodeficiency vi-
rus (HIV) infection have declined.1
However, many patients find it difficult to
comply with long-term HAART,2,3 espe-
cially if they experience adverse effects.4,5
Treatment interruptions in patients
with HIV infections are being studied for
3 main reasons.6 (1) An increase in time
off drug treatment may improve quality of
life and diminish adverse effects and costs.
(2) After HIV has become resistant to an-
tiretroviral drugs, treatment interrup-
tions may allow repopulation of plasma
with drug-susceptible virus and there-
fore improve the chances of success of sub-
sequent salvage therapy.7,8 (3) Reexpo-
sure to viral antigens during treatment
interruption may stimulate anti-HIV im-
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mune responses and allow withdrawal of drugs with sta-
bilization of viremia at low levels.9,10 This is what we call
the “autovaccination hypothesis.”
Rosenberg et al10 described 8 patients who had started
treatment within weeks of infection, and whose viral load
decreased to below 50 copies/mL while receiving HAART.
Following treatment interruptions, 5 of 8 patients re-
mained with plasma viremia below 500 copies/mL after
a mean of 6.5 months without therapy. It is unknown
whether similar results could be achieved in the more
numerous patients who started therapy later, during
chronic HIV infection.
To test the autovaccination hypothesis, as well as
the feasibility and safety of planned treatment interrup-
tions, we prospectively recruited patients whose HAART,
started during chronic HIV infection, had been proven
effective. To maximize potential immune stimulation, the
Swiss-Spanish Intermittent Treatment Trial (SSITT) in-
cluded several cycles of treatment interruptions and treat-
ment, before stopping therapy for a longer period of time.
The HIV-specific CD8+ T-cell responses were measured
and correlated with the level of viremia during periods
without HAART.
METHODS
INCLUSION AND EXCLUSION CRITERIA
Patients had to have received antiretroviral therapy, with an
“undetectable” viral load (50 or 400 copies/mL, depend-
ing on the procedure of the test used) for at least 6 months,
and a viral load of less than 50 copies/mL at enrollment. The
CD4 cell count had to exceed 300/µL at enrollment. Patients
were not eligible for SSITT if they had ever changed treatment
because of virologic failure or had ever received nonnucleo-
side reverse transcriptase inhibitors (NRTIs). By design, half
the patients had a pretreatment nadir of CD4 cell counts be-
low 400/µL.
Viremia was measured using the Amplicor Monitor test
version 1.5 (Roche Diagnostics, Rotkreuz, Switzerland): in its
ultrasensitive procedure (limit of detection, 50 copies/mL)
while patients were on treatment, and in the standard format
(limit of detection, 200 copies/mL) during treatment interrup-
tions. The pre-HAART viral load was the measurement closest
to initiating HAART (66 patients). If more than 1 measure-
ment was available in the 6 months before starting HAART, the
average of the last 2 values was taken as the pre-HAART viral
load.
TREATMENT SCHEDULE AND DEFINITION
OF “RESPONSE”
The treatment schedule is shown in Figure 1. HAART was
interrupted for 2 weeks, restarted, and continued for 8 weeks,
and after 4 such cycles, treatment was indefinitely suspended
at week 40 after study entry. If viral load remained above 50
copies/mL after 8 weeks’ retreatment, patients did not un-
dergo further treatment interruptions. At week 40, treatment
was also restarted if CD4 cell counts were below 400/µL. Oth-
erwise, at week 40, treatment was stopped. From week 40 to
week 52, restarting treatment was recommended if symptoms
of acute HIV infection occurred or if viral load exceeded 50000
copies/mL 3 times, 100000 copies/mL twice, or 500000 cop-
ies/mL once. The drugs used for each individual patient re-
mained identical between weeks 0 and 52, unless a change was
indicated because of viral escape (n=1, see below) or drug in-
tolerance.
At week 52, patients who had undergone four 2-week and
one 12-week treatment interruption were classified as “re-
sponders” if their viral load was below 5000 copies/mL. If their
viral load was higher, or if they had stopped treatment inter-
ruptions for any reason before week 52 they were considered
“nonresponders.” The protocol recommended HAART for non-
responders, and for responders whose viral load rebounded
above 5000 copies/mL after week 52. From week 52 to week
64, viral load and CD4 cell counts were measured every 4 weeks,
and every 8 weeks from week 64 to week 96.
MEASUREMENT OF HIV-SPECIFIC CD8 CYTOTOXIC
T-LYMPHOCYTE RESPONSE, HLA TYPING,
AND LYMPHOCYTE TYPING
The HIV-specific CD8+ T-cell frequencies were determined on
frozen peripheral blood mononuclear cells, by direct ex vivo
interferon  enzyme-linked immunospot analysis.11,12 Syn-
thetic peptides corresponding to previously described optimal
HLA class I–restricted cytotoxic T-lymphocyte epitopes were
used at a concentration of 2mM. According to the HLA geno-
type, each patient was screened at each time point for re-
sponses to a median of 16 (range, 2-32) different cytotoxic T-
lymphocyte epitopes (the list of peptide epitopes is available
from the authors). Results were expressed as spot-forming cells
per million peripheral blood lymphocytes (SFC/106 PBL). A posi-
tive response to a given peptide epitope was defined as SFC/
106 PBL greater than 3 SEs above background and equal to or
above 50 SFC/106 PBL. HLA type was determined by gene am-
plification.13 CD3, CD4, and CD8 lymphocyte counts were de-
termined by flow cytometry (Coulter EPICS IV, Basel, Swit-
zerland) using fluoresceinated DAKO-T3, DAKO-T8, and
R-Phycoerythrin DAKO-CD4 (Dako Corp, Glostrup, Denmark).
RESISTANCE TESTING
Resistance was defined as the occurrence of mutations associ-
ated with resistance in the reverse transcriptase or protease
genes,14,15 whereas “virologic escape” was defined as a viral load
133 Patients
4 Cycles, 2 Weeks Off, 8 Weeks On
43 Do Not Continue:
30 VL >50 After “On” Period
4 CD4 Count < 400/µL Week 39 
9 Other Reasons
11 Resume Treatment
9 High VL
2 Other Reasons
Week 0
Week 40
Week 52 56 With VL >5000 23 With VL <5000 
(Responders)
13 With VL >5000 10 With VL <5000 Week 96
Complete 4 Cycles and Stop HAART at Week 40
90
79
Figure 1. Trial profile. VL indicates viral load (given in copies per milliliter);
HAART, highly active antiretroviral treatment.
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above 500 copies/mL in patients who were compliant with
HAART, after at least 4 months of continuous treatment. Com-
pliance was assessed by the number of prescriptions filled and
by patient interview.
STATISTICAL ANALYSIS
Participants were described using simple statistics (propor-
tions with 95% confidence intervals, means, medians, and
ranges). Viral loads and CD4 cell counts were compared using
nonparametric tests for matched data (Friedman test to com-
pare 4 cycles, Wilcoxon test for paired comparisons); propor-
tions of participants with a viral load greater than 200 cop-
ies/mL were compared using the Cochran Q test (to compare
4 cycles) and McNemar tests (paired comparisons). Baseline
characteristics of responders were compared with those of non-
responders using Mann-Whitney tests (for continuous vari-
ables) and 2 tests (for discrete variables). We also compared
the HIV-specific cytotoxic response (ie, the number of HIV-
specific interferon –producing CD8+ T lymphocytes) in re-
sponders and nonresponders at week 52, and examined the
Spearman correlation between cytotoxic response and the cu-
mulated exposure to the HIV antigen (estimated by the sum of
the heights of rebounds in viral load at weeks 2 to 42). All cal-
culations were done with SPSS version 9.0 statistical software
(SPSS Inc, Chicago, Ill).
RESULTS
PATIENT CHARACTERISTICS
Ninety-two men and 41 women were recruited. Thirty-
six (27%) were from several hospitals in Spain, mostly
in Barcelona, and 97 (73%) were from Switzerland
(Zurich, 29; Geneva, 26; Bern, 11; Basel, 11; St Gall, 8;
Lugano, 7; and Lausanne, 5). Ninety-two (69%) were men.
The probable route of acquisition of HIV was homo-
sexual intercourse in 38%, heterosexual intercourse in
45%, and intravenous drug abuse in 17%. Most (83%)
had always been asymptomatic, with pretreatment CD4
cell counts ranging from 1/µL to 1892/µL (median, 398/
µL), and the log10 of the pretreatment viral load ranging
from 2.2 to 6.2 copies/mL (median, 4.5 copies/mL).
The median duration of HAART at study entry was
26 months (range, 8.5-44.5 months) with undetectable
viral load for a median of 21 months (range, 6-43 months).
The treatment before SSITT consisted of nelfinavir, in-
dinavir, or ritonavir plus 2 NRTIs in 88.5% of patients;
of ritonavir plus saquinavir plus 2 NRTIs in 4%; and of
2 NRTIs without protease inhibitors in 7.5%. At the start
of SSITT the median CD4 cell count was 740/µL (range,
318-1909/µL).
VIRAL LOAD THROUGH 4 CYCLES OF
TREATMENT INTERRUPTION
Of the 133 patients who started SSITT, 43 (32%) left the
study protocol before week 40: 30 because their viral load
did not decrease to less than 50 copies/mL 8 weeks after
restarting treatment; 4 because their CD4 cell counts were
less than 400/µL at week 39 (Figure 1); 8 withdrew con-
sent; and 1 died of chronic hepatitis C. Hence, 90 (68%)
patients completed all 4 cycles.
We compared viral loads during the 5 treatment in-
terruptions at weeks 2, 12, 22, 32, and 42, restricting
analysis to 86 patients for whom all 5 values were avail-
able. There were no significant differences, either in the
proportion of patients having a detectable rebound (200
copies/mL) (ranging from 60% to 66%; Cochran test,
P=.7) or in the height of the median rebound (2.7 to 3
log10; Friedman test, P=.25).
After 4 cycles of stopping and starting therapy again,
HAART was definitively suspended at week 40. The per-
centage of patients who experienced viral load rebound
(200 copies/mL) was 86% at week 44, and 97% at week
46. In 65% of patients, viral load peaked and then fell
spontaneously by greater than 0.5 logs before week 52;
in the other patients viral load rose and then remained
stable (variation of 0.5 logs between peak measured vi-
ral load, and viral load at week 52).
ANALYSIS OF RESPONDERS
VS NONRESPONDERS
Results were analyzed at the protocol-defined time point,
ie, week 52 (after 12 weeks off treatment). Twenty-
three (17%) of the 133 patients (95% confidence inter-
val, 11%-25%) were responders at week 52. Among the
115 patients with a pretreatment viral load of greater than
5000 copies/mL, the response rate was 14% (95% con-
fidence interval, 8%-22%).
Among the 110 nonresponders, 43 did not con-
tinue the study protocol before week 40. An additional
11 restarted treatment between weeks 40 and 52, 9 be-
cause of an excessive rebound of viremia and 2 for other
reasons. Fifty-six additional patients were nonre-
sponders because their viral load at week 52 exceeded
5000 copies/mL.
Responders differed from nonresponders with re-
gard to viral load before HAART (median, 4.09 logs vs
4.57 logs in nonresponders; Mann-Whitney test, P=.001).
None of the 44 patients with a pre-HAART viral load of
more than 60000 copies/mL was a responder (Figure2).
The proportion of patients experiencing rebounds
during weeks 0 to 42 also differed between responders
and nonresponders (Table).
There was a tendency for responders to have started
HAART earlier than nonresponders, with 10 of (44%) 23
responders starting within 2 years of the probable date
of infection, compared with 24 (23%) of 103 nonre-
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Figure 2. Viral load before highly active antiretroviral treatment in
responders and nonresponders. P=.001.
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sponders (P=.10). Six patients (2 responders and 4 non-
responders) had started HAART within 3 months of sero-
conversion. No correlation could be established between
response and pre-HAART CD4 cell counts (responders:
median, 441/µL; range, 131-745/µL; nonresponders: me-
dian, 392/µL; range, 1-1892/µL [P=.7]), and CD4 cell
counts at start of SSITT (responders: median, 752/µL; non-
responders: median, 744/µL [P=.8]).
We compared viral loads after 12 weeks’ treatment
interruption (at week 52) with the last viral load before
starting HAART. Eighteen (13.5%) of 133 had a viral load
less than 5000 copies/mL before HAART, and 25 (19%)
at week 52 (McNemar test, P=.2).
LONG-TERM FOLLOW-UP
All 23 responders continued to be followed up without
HAART. At the second protocol-specified time point
(week 96), 10 (8%) of the original collective of 133 pa-
tients still had a viral load below 5000 copies/mL, with-
out antiretroviral treatment.
For nonresponders, the protocol (written in 1999)
specified reintroduction of HAART at week 52. How-
ever, because official guidelines for antiviral therapy had
changed in the meantime,16 many nonresponders elected
not to start treatment again. Among all 133 patients start-
ing SSITT, the percentage of those without treatment was
64% at week 52 and 41% at week 96.
SAFETY OF TREATMENT INTERRUPTION
No major (Centers for Disease Control and Prevention
[CDC] class C17) or minor (CDC class B17) HIV-related
opportunistic diseases were observed during SSITT.
CD4 Cell Counts in the Absence of HAART
There was a slight rise of CD4 cell counts after the 4 cycles
of short treatment interruptions (medians, 759/µL at week
0 and 792/µL at week 40; paired Wilcoxon test, P=.02).
After suspension of HAART at week 40, median CD4 cell
counts decreased from 792/µL to 615/µL at week 52
(P.001). The decrease was observed in both respond-
ers (from 699 to 549/µL; P=.002) and nonresponders
(from 860 to 618/µL; P.001), and was greater in non-
responders (P=.01, Mann-Whitney test).
After week 52, the fall in median CD4 cell counts
was slower: from 625/µL at week 52 to 569/µL at last fol-
low-up after a median of 56 weeks without treatment
(P=.01, paired Wilcoxon test). Nonresponders went from
a median of 643/µL at week 52 to 564/µL (P.005),
whereas responders showed a nonsignificant increase from
549/µL to 574/µL. The difference in CD4 cell count
changes between responders and nonresponders did not
reach statistical significance (P=.13, Mann-Whitney test).
Viral Escape and Resistance
One (0.7%) of 133 patients developed virologic escape.
He had a viral load of 141 copies/mL at week 9 and had
no further treatment interruptions. He continued his
initial treatment (a combination of lamivudine, zidovu-
dine, and nelfinavir); his viral load rose to 2730
copies/mL after a further 23 weeks. His treatment was
changed to a regimen of stavudine, efavirenz, abacavir,
and saquinavir boosted with ritonavir, with a decrease
of the viral load to less than 10 copies/mL after a further
6 weeks.
The protocol specified viral genotyping for all pa-
tients with virologic escape, and for all patients from
Geneva. The 1 patient with virologic escape had the 184V
mutation in the reverse transcriptase (RT) gene, and mul-
tiple mutations in the protease gene before he was
switched to salvage treatment. Of the 24 Geneva pa-
tients, 8 did not continue treatment interruptions be-
tween weeks 0 and 40 because viral load remained above
50 copies/mL after retreatment. In these patients, we ana-
lyzed the viral genotype during the last viral rebound be-
fore discontinuing treatment interruptions. Regarding the
RT gene, viruses from 3 patients were wild type, and 5
had the 184 mutation. When the earliest available sample
(week 2) was analyzed in these 5 patients, the 184 mu-
tation was already present in 3. There were no relevant
mutations in the protease gene.
In the remaining 16 patients from Geneva, who sus-
pended treatment at week 40, the HIV genotype was de-
termined when the viremia first exceeded 1000 cop-
ies/mL (weeks 42 to 46). Regarding the protease gene,
viruses from 16 patients had wild-type sequences, or mi-
nor variants corresponding to polymorphism. Regard-
ing the RT gene, in 1 patient the virus had multiple RT
mutations (41L, 67N, 210W, 215Y). He had been treated
with zidovudine for several months, 7 years before SSITT.
Had this been known before, he would not have been in-
cluded in SSITT.
Occurrence of the Acute Retroviral Syndrome
Symptoms resembling those of the acute retroviral syn-
drome may occur during treatment interruptions.18 Two
patients developed fever, skin lesions, and pharyngitis
in association with viremia above 500000 copies/mL.
Symptoms resolved promptly upon retreatment, and these
2 patients did not continue the protocol.
Presence/Absence of Rebound and Probability of Response
Rebound Status Total No. Responders, No. (%) Nonresponders, No. (%) P Value
With rebound at week 2 88 8 (9) 80 (91)
.001
With no rebound at week 2 45 15 (33) 30 (67)
With at least 1 rebound at weeks 2, 12, 22, 32, or 42 71 12 (17) 59 (83)
.001
With no rebound at week 2, 12, 22, 32, and 42 15 10 (67) 5 (33)
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Although patients were warned about the impor-
tance of using condoms, there was one instance of prob-
able transmission of HIV.19
Results of Retreatment After SSITT
Eighty-two patients restarted treatment after SSITT. When
last checked 3 to 6 months after starting treatment again,
68 had an “undetectable” viral load less than 200 copies/
mL, 12 had a detectable viral load above 200 copies/mL
but were either off drugs or noncompliant, 1 patient (men-
tioned above) was receiving salvage therapy after viral
escape, and 1 was lost to follow-up.
HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES
The HIV-specific CD8+ T-cell responses are shown in
Figure 3A. The median number of HIV-specific, inter-
feron –producing CD8+ T lymphocytes increased from 343
per million at week 0 to 1930 per million at week 52 (paired
Wilcoxon test, P.001 compared with week 0).
At week 52, responders had a median of 813 SFC/
106 PBL, whereas nonresponders had a median of 2999
(Mann-Whitney test, P=.01; Figure 3B). The number of
SFC at week 52 correlated with the degree of antigen ex-
posure, as measured by the mean of the rebounds in vi-
ral load at weeks 2 to 42 (Spearman coefficient r=0.38,
P=.002).
COMMENT
Results of the SSITT do not favor the autovaccination hy-
pothesis. Viral loads after SSITT were similar to those be-
fore HAART. Response was more frequent in patients who
showed few, or no rebounds during on-off cycling (Table
1). Increases in HIV-specific CD8+ T-cell frequencies did
not correlate with control of viral replication (low viral
load) at week 52. Indeed, there was a statistically signifi-
cant trend in the other direction: nonresponders tended
to have more SFCs at week 52 than responders. Direct
correlation of CD8+ HIV-specific T-cell response and vi-
ral load has also been shown in untreated chronic HIV
infection and most probably reflect the extent of anti-
gen exposure.20 Our findings do not exclude the possi-
bility that changes in other components of the immune
response, not measured here, might predict viremia dur-
ing treatment interruptions.
The patients who were eligible for SSITT are repre-
sentative of a population commonly found in clinical prac-
tice. Ninety-five percent had started HAART after the acute
retroviral syndrome had passed, usually years after in-
fection. Half had been immunosuppressed (400 CD4
cells/µL) before HAART. Treatment before SSITT had been
effective, as evidenced by a viral load that had remained
undetectable for a median of 21 months, and a CD4 cell
count that had risen from a median of 398/µL to a me-
dian of 740/µL. Among 5248 patients receiving HAART
in the Swiss HIV Cohort Study in August 2001, 1405
(27%) had been antiretroviral-naive before HAART, had
had a viral load below the limits of detection for at least
6 months, and had never changed therapy because of a
rise in viral load. It is to these patients that the results of
SSITT are potentially applicable.
About 1 in 6 participants was a “responder,” with a
viral load less than 5000 copies/mL at week 52, after 12
weeks off treatment. Viremia was significantly lower be-
fore initiation of HAART in responders than in nonre-
sponders (P.001). Contrary to expectations, the pres-
ence or absence of immunodeficiency before HAART did
not seem to make a difference, as the pre-HAART CD4
cell counts were similar among responders and nonre-
sponders.
Many additional nonresponding patients stayed off
therapy for varying periods, up to more than 1 year. In
the absence of HAART, CD4 cell counts fell rapidly dur-
ing the first 12 weeks, then stabilized. Patients in SSITT
stopped therapy when the CD4 cell count was relatively
high (median of 740/µL), so that the fall during the first
12 weeks did not have clinical consequences. These re-
sults suggest that a substantial minority of patients who
are presently treated with HAART can safely discon-
tinue the drugs for several months without undue rise
in viremia or a dangerous fall in CD4 cell counts. How-
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Figure 3. Results of enzyme-linked immunospot analysis in all 71 patients
for whom results from weeks 0 and 52 were available. A, Numbers of human
immunodeficiency virus–specific, interferon –producing, CD8+
spot-forming cells per million peripheral blood lymphocytes (HIV-IFN-CD8+
SFC/106 PBL) from weeks 0 to 52. B, Numbers of SFC/106 PBL (and median)
at week 52 in responders and nonresponders. All patients stayed off therapy
between weeks 40 and 52. Responders have statistically lower number of
SFC than nonresponders (P=.01, Mann-Whitney test).
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ever, whether such discontinuation is beneficial or harm-
ful can only be determined in future studies, with ran-
domized comparison of continuous with intermittent
treatment.
Indeed, one important question may arise regard-
ing the study design: Why did the SSITT not include con-
trol groups? Two types of controls were considered: (1)
A “simple-stop” control group would have stopped treat-
ment without on-off cycling. Preliminary inquiries indi-
cated that a simple-stop group would not be approved
by institutional review boards in 1999, because of then
current guidelines that mandated continued treatment
for almost all HIV-infected patients. 21
(2) Another possible control group would have re-
ceived continuous therapy, the current standard. With
a total of 133 patients, such a comparison between con-
tinued and intermittent therapy would have lacked power
and could only have detected improbably large differ-
ences between groups. It would have halved the num-
ber of patients in the intermittent treatment group and
would have endangered attainment of our primary goal,
which was to explore the correlation between HIV-
specific immune response and control of viremia with-
out therapy. We therefore believe that the study design
was well adapted to the goals of the study.
Were the 2-week interruptions optimal to stimu-
late HIV-specific immunity, or would longer interrup-
tions have been more productive? We decided on 2 weeks
because previous experience indicated that most pa-
tients would show a rebound22-25; and because longer in-
terruptions might be associated with an increased risk
of the acute retroviral syndrome26 and might depress,
rather than enhance, HIV-specific immune responses.27
Rebounds after 2 weeks were measurable in 88 of our pa-
tients (66%), and 2 instances of the acute retroviral syn-
drome occurred. The HIV-specific CD8+ T-cell frequen-
cies, as measured by interferon  enzyme-linked
immunospot analysis, were enhanced. It seems there-
fore unlikely that changing the duration of interrup-
tions would have produced substantially different re-
sults.
Treatment interruption was quite safe in this popu-
lation in that no opportunistic events and little viral re-
sistance were observed. It should be noted, however, that
SSITT did not enroll patients who had been exposed to
partially effective treatment before HAART, thus elimi-
nating a group at high risk for development of resis-
tance.28
The SSITT lends perspective to some previously re-
ported studies with smaller numbers of patients. In com-
parison to patients who started their treatment during
acute HIV infection,10 the frequency of response ap-
pears lower in the SSITT patients. In contrast to the study
by Lori et al,25 we found no evidence that the time until
detection of rebound increased. Lori et al observed an
increase in time to rebound, during successive treat-
ment interruptions in 3 patients, to above 20 days. In our
study, such an increase would have produced an increas-
ing proportion of patients without rebound during the
four 2-week treatment interruptions from week 0 to week
40. However, the proportion of patients with rebound
remained similar.
Results of SSITT show that iterative treatment in-
terruptions by themselves are rarely sufficient to attain
the goal of low, or even undetectable, viremia without
antiretroviral therapy. Additional measures such as non-
specific immune stimulation using cytokines (in anal-
ogy to cancer vaccinology)29 or specific immune stimu-
lation through therapeutic vaccination30,31 should be
explored.
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